Mouse models for liver cancer

Molecular Oncology

Volumn 7, Issue 2, 2013, Pages 206-223

  Bakiri, Latifa ^a   Wagner, Erwin F ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

Hepatocellular carcinoma models; Liver cancer; Mouse models

Indexed keywords

FATTY ACID; FIBRIC ACID DERIVATIVE; HERBICIDE; ICOSANOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PLASTICIZER; POLYPROTEIN; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR AP 1;

ADENO ASSOCIATED VIRUS; BACTERIAL TRANSLOCATION; CANCER GENETICS; CANCER INCIDENCE; CHEMICAL CARCINOGENESIS; DIABETES MELLITUS; DNA DAMAGE; DNA MODIFICATION; DNA VIRUS; EXPERIMENTAL MOUSE; GENDER BIAS; GENE EXPRESSION; GENE TARGETING; GENETIC ENGINEERING; HEPATITIS; HEPATITIS B VIRUS; HEPATITIS C; HIGH RISK POPULATION; IMMUNOMODULATION; INTESTINE FLORA; KNOCKOUT MOUSE; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER METABOLISM; MOSAICISM; MOUSE STRAIN; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; REVIEW; TRANSGENIC MOUSE; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE;

EID: 84875810895     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.01.005     Document Type: Review

References (171)

1. Aleksic K., Lackner C., Geigl J.B., Schwarz M., Auer M., Ulz P., et al. Evolution of genomic instability in diethylnitrosamine-induced hepatocarcinogenesis in mice. Hepatology 2011, 53:895-904.
2. Asano T., Watanabe K., Kubota N., Gunji T., Omata M., Kadowaki T., et al. Adiponectin knockout mice on high fat diet develop fibrosing steatohepatitis. J. Gastroenterol. Hepatol. 2009, 24:1669-1676.
3. Aydinlik H., Nguyen T.D., Moennikes O., Buchmann A., Schwarz M. Selective pressure during tumor promotion by phenobarbital leads to clonal outgrowth of beta-catenin-mutated mouse liver tumors. Oncogene 2001, 20:7812-7816.
4. Babinet C., Farza H., Morello D., Hadchouel M., Pourcel C. Specific expression of hepatitis B surface antigen (HBsAg) in transgenic mice. Science 1985, 230:1160-1163.
5. Baffy G., Brunt E.M., Caldwell S.H. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J. Hepatol. 2012, 56:1384-1391.
6. Behrens A., Sibilia M., David J.P., Mohle-Steinlein U., Tronche F., Schutz G., et al. Impaired postnatal hepatocyte proliferation and liver regeneration in mice lacking c-jun in the liver. EMBO J. 2002, 21:1782-1790.
7. Bell J.B., Podetz-Pedersen K.M., Aronovich E.L., Belur L.R., McIvor R.S., Hackett P.B. Preferential delivery of the sleeping beauty transposon system to livers of mice by hydrodynamic injection. Nat. Protoc. 2007, 2:3153-3165.
8. Ben-Neriah Y., Karin M. Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat. Immunol. 2011, 12:715-723.
9. Bradley A., Anastassiadis K., Ayadi A., Battey J.F., Bell C., Birling M.C., et al. The mammalian gene function resource: the international knockout mouse consortium. Mamm. Genome 2012, 23:580-586.
10. Brenner D.A. Molecular pathogenesis of liver fibrosis. Trans. Am. Clin. Climatol. Assoc. 2009, 120:361-368.
11. Cadoret A., Ovejero C., Saadi-Kheddouci S., Souil E., Fabre M., Romagnolo B., et al. Hepatomegaly in transgenic mice expressing an oncogenic form of beta-catenin. Cancer Res. 2001, 61:3245-3249.
12. Caldwell S.H., Crespo D.M., Kang H.S., Al-Osaimi A.M. Obesity and hepatocellular carcinoma. Gastroenterology 2004, 127:S97-S103.
13. Calvisi D.F., Ladu S., Gorden A., Farina M., Conner E.A., Lee J.S., et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 2006, 130:1117-1128.
14. Chayama K., Hayes C.N., Hiraga N., Abe H., Tsuge M., Imamura M. Animal model for study of human hepatitis viruses. J. Gastroenterol. Hepatol. 2011, 26:13-18.
15. Chen B., Liu L., Castonguay A., Maronpot R.R., Anderson M.W., You M. Dose-dependent ras mutation spectra in N-nitrosodiethylamine induced mouse liver tumors and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced mouse lung tumors. Carcinogenesis 1993, 14:1603-1608.
16. Cheung C., Akiyama T.E., Ward J.M., Nicol C.J., Feigenbaum L., Vinson C., et al. Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated receptor alpha. Cancer Res. 2004, 64:3849-3854.
17. Cheung C., Gonzalez F.J. Humanized mouse lines and their application for prediction of human drug metabolism and toxicological risk assessment. J. Pharmacol. Exp. Ther. 2008, 327:288-299.
18. Chisari F.V., Klopchin K., Moriyama T., Pasquinelli C., Dunsford H.A., Sell S., et al. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 1989, 59:1145-1156.
19. Chisari F.V., Pinkert C.A., Milich D.R., Filippi P., McLachlan A., Palmiter R.D., et al. A transgenic mouse model of the chronic hepatitis B surface antigen carrier state. Science 1985, 230:1157-1160.
20. Chrousos G.P. Stress and sex versus immunity and inflammation. Sci. Signal. 2010, 3:pe36.
21. Chu R., Lim H., Brumfield L., Liu H., Herring C., Ulintz P., et al. Protein profiling of mouse livers with peroxisome proliferator-activated receptor alpha activation. Mol. Cell. Biol. 2004, 24:6288-6297.
22. Clemente J.C., Ursell L.K., Parfrey L.W., Knight R. The impact of the gut microbiota on human health: an integrative view. Cell 2012, 148:1258-1270.
23. Colak D., Chishti M.A., Al-Bakheet A.B., Al-Qahtani A., Shoukri M.M., Goyns M.H., et al. Integrative and comparative genomics analysis of early hepatocellular carcinoma differentiated from liver regeneration in young and old. Mol. Cancer 2010, 9:146.
24. Colnot S., Decaens T., Niwa-Kawakita M., Godard C., Hamard G., Kahn A., et al. Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:17216-17221.
25. Conner E.A., Lemmer E.R., Omori M., Wirth P.J., Factor V.M., Thorgeirsson S.S. Dual functions of E2F-1 in a transgenic mouse model of liver carcinogenesis. Oncogene 2000, 19:5054-5062.
26. Coulouarn C., Factor V.M., Thorgeirsson S.S. Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology 2008, 47:2059-2067.
27. Dapito D.H., Mencin A., Gwak G.Y., Pradere J.P., Jang M.K., Mederacke I., et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012, 21:504-516.
28. Das M., Garlick D.S., Greiner D.L., Davis R.J. The role of JNK in the development of hepatocellular carcinoma. Genes Dev. 2011, 25:634-645.
29. Davit-Spraul A., Gonzales E., Baussan C., Jacquemin E. The spectrum of liver diseases related to ABCB4 gene mutations: pathophysiology and clinical aspects. Semin. Liver Dis. 2010, 30:134-146.
30. Devkota S., Wang Y., Musch M.W., Leone V., Fehlner-Peach H., Nadimpalli A., et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/- mice. Nature 2012, 487:104-108.
31. DiDonato J.A., Mercurio F., Karin M. NF-kappaB and the link between inflammation and cancer. Immunol. Rev. 2012, 246:379-400.
32. Diwan B.A., Rice J.M., Ohshima M., Ward J.M. Interstrain differences in susceptibility to liver carcinogenesis initiated by N-nitrosodiethylamine and its promotion by phenobarbital in C57BL/6NCr, C3H/HeNCrMTV- and DBA/2NCr mice. Carcinogenesis 1986, 7:215-220.
33. Dore G.J. The changing therapeutic landscape for hepatitis C. Med. J. Aust. 2012, 196:629-632.
34. Dorner M., Horwitz J.A., Robbins J.B., Barry W.T., Feng Q., Mu K., et al. A genetically humanized mouse model for hepatitis C virus infection. Nature 2011, 474:208-211.
35. Drinkwater N.R. Genetic control of hepatocarcinogenesis in inbred mice. Genes and Signal Transduction in Multistage Carcinogenesis 1988, 3-17. Marcel Dekker. Inc., New York. N.H. Colburn (Ed.).
36. Dubois N., Bennoun M., Allemand I., Molina T., Grimber G., Daudet-Monsac M., et al. Time-course development of differentiated hepatocarcinoma and lung metastasis in transgenic mice. J. Hepatol. 1991, 13:227-239.
37. Dunsford H.A., Sell S., Chisari F.V. Hepatocarcinogenesis due to chronic liver cell injury in hepatitis B virus transgenic mice. Cancer Res. 1990, 50:3400-3407.
38. Eferl R., Ricci R., Kenner L., Zenz R., David J.P., Rath M., et al. Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell 2003, 112:181-192.
39. Ehlken H., Kondylis V., Heinrichsdorff J., Ochoa-Callejero L., Roskams T., Pasparakis M. Hepatocyte IKK2 protects Mdr2-/- mice from chronic liver failure. PLoS One 2011, 6:e25942.
40. Fan B., Malato Y., Calvisi D.F., Naqvi S., Razumilava N., Ribback S., et al. Cholangiocarcinomas can originate from hepatocytes in mice. J. Clin. Invest. 2012, 122:2911-2915.
41. Fan C.Y., Pan J., Chu R., Lee D., Kluckman K.D., Usuda N., et al. Hepatocellular and hepatic peroxisomal alterations in mice with a disrupted peroxisomal fatty acyl-coenzyme A oxidase gene. J. Biol. Chem. 1996, 271:24698-24710.
42. Farazi P.A., DePinho R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 2006, 6:674-687.
43. Feinstone S.M., Hu D.J., Major M.E. Prospects for prophylactic and therapeutic vaccines against hepatitis C virus. Clin. Infect. Dis. 2012, 55(Suppl. 1):S25-S32.
44. Feng G.J., Cotta W., Wei X.Q., Poetz O., Evans R., Jarde T., et al. Conditional disruption of Axin1 leads to development of liver tumors in mice. Gastroenterology 2012, 143:1650-1659.
45. Feng G.S. Conflicting roles of molecules in hepatocarcinogenesis: paradigm or paradox. Cancer Cell 2011, 21:150-154.
46. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127:2893-2917.
47. Fox J.G., Feng Y., Theve E.J., Raczynski A.R., Fiala J.L., Doernte A.L., et al. Gut microbes define liver cancer risk in mice exposed to chemical and viral transgenic hepatocarcinogens. Gut 2010, 59:88-97.
48. Hanahan D., Wagner E.F., Palmiter R.D. The origins of oncomice: a history of the first transgenic mice genetically engineered to develop cancer. Genes Dev. 2007, 21:2258-2270.
49. Hasselblatt P., Rath M., Komnenovic V., Zatloukal K., Wagner E.F. Hepatocyte survival in acute hepatitis is due to c-Jun/AP-1-dependent expression of inducible nitric oxide synthase. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:17105-17110.
50. Haugen F., Drevon C.A. Activation of nuclear factor-kappaB by high molecular weight and globular adiponectin. Endocrinology 2007, 148:5478-5486.
51. Haybaeck J., Zeller N., Wolf M.J., Weber A., Wagner U., Kurrer M.O., et al. A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell 2009, 16:295-308.
52. He G., Karin M. NF-kappaB and STAT3-key players in liver inflammation and cancer. Cell. Res. 2011, 21:159-168.
53. Herranz D., Munoz-Martin M., Canamero M., Mulero F., Martinez-Pastor B., Fernandez-Capetillo O., et al. Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat. Commun. 2010, 1:3.
54. Hilberg F., Aguzzi A., Howells N., Wagner E.F. c-jun is essential for normal mouse development and hepatogenesis. Nature 1993, 365:179-181.
55. Hill-Baskin A.E., Markiewski M.M., Buchner D.A., Shao H., DeSantis D., Hsiao G., et al. Diet-induced hepatocellular carcinoma in genetically predisposed mice. Hum. Mol. Genet. 2009, 18:2975-2988.
56. Ho C., Wang C., Mattu S., Destefanis G., Ladu S., Delogu S., et al. AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2, and c-Myc pathways. Hepatology 2012, 55:833-845.
57. Hoshida Y., Villanueva A., Kobayashi M., Peix J., Chiang D.Y., Camargo A., et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N. Engl. J. Med. 2008, 359:1995-2004.
58. Hotamisligil G.S., Budavari A., Murray D., Spiegelman B.M. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J. Clin. Invest. 1994, 94:1543-1549.
59. Hu W., Feng Z., Eveleigh J., Iyer G., Pan J., Amin S., et al. The major lipid peroxidation product, trans-4-hydroxy-2-nonenal, preferentially forms DNA adducts at codon 249 of human p53 gene, a unique mutational hotspot in hepatocellular carcinoma. Carcinogenesis 2002, 23:1781-1789.
60. Huang H., Shiffman M.L., Friedman S., Venkatesh R., Bzowej N., Abar O.T., et al. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology 2007, 46:297-306.
61. Huang W., Ma K., Zhang J., Qatanani M., Cuvillier J., Liu J., et al. Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science 2006, 312:233-236.
62. Hui L., Bakiri L., Mairhorfer A., Schweifer N., Haslinger C., Kenner L., et al. p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat. Genet. 2007, 39:741-749.
63. Hui L., Zatloukal K., Scheuch H., Stepniak E., Wagner E.F. Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J. Clin. Invest. 2008, 118:3943-3953.
64. Inagaki T., Choi M., Moschetta A., Peng L., Cummins C.L., McDonald J.G., et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell. Metab. 2005, 2:217-225.
65. Ivanovska I., Zhang C., Liu A.M., Wong K.F., Lee N.P., Lewis P., et al. Gene signatures derived from a c-MET-driven liver cancer mouse model predict survival of patients with hepatocellular carcinoma. PLoS One 2011, 6:e24582.
66. Jhappan C., Stahle C., Harkins R.N., Fausto N., Smith G.H., Merlino G.T. TGF alpha overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas. Cell 1990, 61:1137-1146.
67. Johnson R.S., van Lingen B., Papaioannou V.E., Spiegelman B.M. A null mutation at the c-jun locus causes embryonic lethality and retarded cell growth in culture. Genes Dev. 1993, 7:1309-1317.
68. Kalra M., Mayes J., Assefa S., Kaul A.K., Kaul R. Role of sex steroid receptors in pathobiology of hepatocellular carcinoma. World J. Gastroenterol. 2008, 14:5945-5961.
69. Kamada Y., Matsumoto H., Tamura S., Fukushima J., Kiso S., Fukui K., et al. Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model. J. Hepatol. 2007, 47:556-564.
70. Kang T.W., Yevsa T., Woller N., Hoenicke L., Wuestefeld T., Dauch D., et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 2012, 479:547-551.
71. Kaposi-Novak P., Libbrecht L., Woo H.G., Lee Y.H., Sears N.C., Coulouarn C., et al. Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. Cancer Res. 2009, 69:2775-2782.
72. Katzenellenbogen M., Mizrahi L., Pappo O., Klopstock N., Olam D., Jacob-Hirsch J., et al. Molecular mechanisms of liver carcinogenesis in the mdr2-knockout mice. Mol. Cancer Res. 2007, 5:1159-1170.
73. Katzenellenbogen M., Pappo O., Barash H., Klopstock N., Mizrahi L., Olam D., et al. Multiple adaptive mechanisms to chronic liver disease revealed at early stages of liver carcinogenesis in the Mdr2-knockout mice. Cancer Res. 2006, 66:4001-4010.
74. Kenzelmann Broz D., Attardi L.D. In vivo analysis of p53 tumor suppressor function using genetically engineered mouse models. Carcinogenesis 2010, 31:1311-1318.
75. Khan M., Jahan S., Khaliq S., Ijaz B., Ahmad W., Samreen B., et al. Interaction of the hepatitis C virus (HCV) core with cellular genes in the development of HCV-induced steatosis. Arch. Virol. 2010, 155:1735-1753.
76. Kim C.M., Koike K., Saito I., Miyamura T., Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991, 351:317-320.
77. Kota J., Chivukula R.R., O'Donnell K.A., Wentzel E.A., Montgomery C.L., Hwang H.W., et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009, 137:1005-1017.
78. Lazo M., Clark J.M. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin. Liver Dis. 2008, 28:339-350.
79. Lee J.S., Chu I.S., Mikaelyan A., Calvisi D.F., Heo J., Reddy J.K., et al. Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat. Genet. 2004, 36:1306-1311.
80. Lee J.S., Grisham J.W., Thorgeirsson S.S. Comparative functional genomics for identifying models of human cancer. Carcinogenesis 2005, 26:1013-1020.
81. Lewis B.C., Klimstra D.S., Socci N.D., Xu S., Koutcher J.A., Varmus H.E. The absence of p53 promotes metastasis in a novel somatic mouse model for hepatocellular carcinoma. Mol. Cell. Biol. 2005, 25:1228-1237.
82. Li Y., Tang Z.Y., Hou J.X. Hepatocellular carcinoma: insight from animal models. Nat. Rev. Gastroenterol. Hepatol. 2011, 9:32-43.
83. Li Z., Tuteja G., Schug J., Kaestner K.H. Foxa1 and Foxa2 are essential for sexual dimorphism in liver cancer. Cell 2012, 148:72-83.
84. Liu N., Meng Z., Lou G., Zhou W., Wang X., Zhang Y., et al. Hepatocarcinogenesis in FXR-/- mice mimics human HCC progression that operates through HNF1alpha regulation of FXR expression. Mol. Endocrinol. 2012, 26:775-785.
85. Liu Y., Li C., Xing Z., Yuan X., Wu Y., Xu M., et al. Proteomic mining in the dysplastic liver of WHV/c-myc mice-insights and indicators for early hepatocarcinogenesis. FEBS J. 2010, 277:4039-4053.
86. Luedde T., Beraza N., Kotsikoris V., van Loo G., Nenci A., De Vos R., et al. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 2007, 11:119-132.
87. Luedde T., Schwabe R.F. NF-kappaB in the liver-linking injury, fibrosis and hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 2011, 8:108-118.
88. Ma W.L., Hsu C.L., Wu M.H., Wu C.T., Wu C.C., Lai J.J., et al. Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma. Gastroenterology 2008, 135:947-955. 955 e1-5.
89. Ma W.L., Hsu C.L., Yeh C.C., Wu M.H., Huang C.K., Jeng L.B., et al. Hepatic androgen receptor suppresses hepatocellular carcinoma metastasis through modulation of cell migration and anoikis. Hepatology 2012, 56:176-185.
90. MacArthur K.L., Wu C.H., Wu G.Y. Animal models for the study of hepatitis C virus infection and replication. World J. Gastroenterol. 2012, 18:2909-2913.
91. Machida K., Tsukamoto H., Liu J.C., Han Y.P., Govindarajan S., Lai M.M., et al. c-Jun mediates hepatitis C virus hepatocarcinogenesis through signal transducer and activator of transcription 3 and nitric oxide-dependent impairment of oxidative DNA repair. Hepatology 2011, 52:480-492.
92. Maeda S., Kamata H., Luo J.L., Leffert H., Karin M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 2005, 121:977-990.
93. Mallon A.M., Iyer V., Melvin D., Morgan H., Parkinson H., Brown S.D., et al. Accessing data from the International Mouse Phenotyping Consortium: state of the art and future plans. Mamm. Genome 2012, 23:641-652.
94. Manickan E., Satoi J., Wang T.C., Liang T.J. Conditional liver-specific expression of simian virus 40 T antigen leads to regulatable development of hepatic neoplasm in transgenic mice. J. Biol. Chem. 2001, 276:13989-13994.
95. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
96. Marks C. Mouse models of human cancers consortium (MMHCC) from the NCI. Dis. Model. Mech. 2009, 2:111.
97. Mauad T.H., van Nieuwkerk C.M., Dingemans K.P., Smit J.J., Schinkel A.H., Notenboom R.G., et al. Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am. J. Pathol. 1994, 145:1237-1245.
98. McGivern D.R., Lemon S.M. Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer. Oncogene 2011, 30:1969-1983.
99. Meyer K., Lee J.S., Dyck P.A., Cao W.Q., Rao M.S., Thorgeirsson S.S., et al. Molecular profiling of hepatocellular carcinomas developing spontaneously in acyl-CoA oxidase deficient mice: comparison with liver tumors induced in wild-type mice by a peroxisome proliferator and a genotoxic carcinogen. Carcinogenesis 2003, 24:975-984.
100. Min L., Ji Y., Bakiri L., Qiu Z., Cen J., Chen X., et al. Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin. Nat. Cell. Biol. 2012, 14:1203-1211.
101. Moriya K., Fujie H., Shintani Y., Yotsuyanagi H., Tsutsumi T., Ishibashi K., et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat. Med. 1998, 4:1065-1067.
102. Moustafa T., Fickert P., Magnes C., Guelly C., Thueringer A., Frank S., et al. Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury. Gastroenterology 2012, 142:140-151 e12.
103. Murakami H., Sanderson N.D., Nagy P., Marino P.A., Merlino G., Thorgeirsson S.S. Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis: interaction of c-myc and transforming growth factor alpha in hepatic oncogenesis. Cancer Res. 1993, 53:1719-1723.
104. Naugler W.E., Sakurai T., Kim S., Maeda S., Kim K., Elsharkawy A.M., et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007, 317:121-124.
105. Nejak-Bowen K.N., Monga S.P. Beta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad. Semin. Cancer Biol. 2011, 21:44-58.
106. Newell P., Villanueva A., Friedman S.L., Koike K., Llovet J.M. Experimental models of hepatocellular carcinoma. J. Hepatol. 2008, 48:858-879.
107. Nicholes K., Guillet S., Tomlinson E., Hillan K., Wright B., Frantz G.D., et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am. J. Pathol. 2002, 160:2295-2307.
108. Nicholson J.K., Holmes E., Kinross J., Burcelin R., Gibson G., Jia W., et al. Host-gut microbiota metabolic interactions. Science 2012, 336:1262-1267.
109. Nordenstedt H., White D.L., El-Serag H.B. The changing pattern of epidemiology in hepatocellular carcinoma. Dig. Liver Dis. 2012, 42(Suppl. 3):S206-S214.
110. Park E.J., Lee J.H., Yu G.Y., He G., Ali S.R., Holzer R.G., et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010, 140:197-208.
111. Pathak A., Vyas S.P., Gupta K.C. Nano-vectors for efficient liver specific gene transfer. Int. J. Nanomedicine 2008, 3:31-49.
112. Peychal S.E., Bilger A., Pitot H.C., Drinkwater N.R. Predominant modifier of extreme liver cancer susceptibility in C57BR/cdJ female mice localized to 6 Mb on chromosome 17. Carcinogenesis 2009, 30:879-885.
113. Pfeilschifter J., Koditz R., Pfohl M., Schatz H. Changes in proinflammatory cytokine activity after menopause. Endocr. Rev. 2002, 23:90-119.
114. Pikarsky E., Porat R.M., Stein I., Abramovitch R., Amit S., Kasem S., et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004, 431:461-466.
115. Pineau P., Volinia S., McJunkin K., Marchio A., Battiston C., Terris B., et al. miR-221 overexpression contributes to liver tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:264-269.
116. Poole T.M., Drinkwater N.R. Strain dependent effects of sex hormones on hepatocarcinogenesis in mice. Carcinogenesis 1996, 17:191-196.
117. Potthoff M.J., Kliewer S.A., Mangelsdorf D.J. Endocrine fibroblast growth factors 15/19 and 21: from feast to famine. Genes Dev. 2012, 26:312-324.
118. Premsrirut P.K., Dow L.E., Kim S.Y., Camiolo M., Malone C.D., Miething C., et al. A rapid and scalable system for studying gene function in mice using conditional RNA interference. Cell 2011, 145:145-158.
119. Prosser H.M., Koike-Yusa H., Cooper J.D., Law F.C., Bradley A. A resource of vectors and ES cells for targeted deletion of microRNAs in mice. Nat. Biotechnol. 2011, 29:840-845.
120. Qi Y., Chen X., Chan C.Y., Li D., Yuan C., Yu F., et al. Two-dimensional differential gel electrophoresis/analysis of diethylnitrosamine induced rat hepatocellular carcinoma. Int. J. Cancer 2008, 122:2682-2688.
121. Rajewsky M.F., Dauber W., Frankenberg H. Liver carcinogenesis by diethylnitrosamine in the rat. Science 1966, 152:83-85.
122. Reed K.R., Athineos D., Meniel V.S., Wilkins J.A., Ridgway R.A., Burke Z.D., et al. B-catenin deficiency, but not Myc deletion, suppresses the immediate phenotypes of APC loss in the liver. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:18919-18923.
123. Ritorto M.S., Borlak J. Combined serum and tissue proteomic study applied to a c-Myc transgenic mouse model of hepatocellular carcinoma identified novel disease regulated proteins suitable for diagnosis and therapeutic intervention strategies. J. Proteome Res. 2011, 10:3012-3030.
124. Rogers A.B. Distance burning: how gut microbes promote extraintestinal cancers. Gut Microbe. 2011, 2:52-57.
125. Romano L., Paladini S., Van Damme P., Zanetti A.R. The worldwide impact of vaccination on the control and protection of viral hepatitis B. Dig. Liver Dis. 2011, 43(Suppl. 1):S2-S7.
126. Sakurai T., He G., Matsuzawa A., Yu G.Y., Maeda S., Hardiman G., et al. Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell 2008, 14:156-165.
127. Sakurai T., Maeda S., Chang L., Karin M. Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:10544-10551.
128. Sandgren E.P., Quaife C.J., Pinkert C.A., Palmiter R.D., Brinster R.L. Oncogene-induced liver neoplasia in transgenic mice. Oncogene 1989, 4:715-724.
129. Sawey E.T., Chanrion M., Cai C., Wu G., Zhang J., Zender L., et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening. Cancer Cell 2011, 19:347-358.
130. Saxena N.K., Fu P.P., Nagalingam A., Wang J., Handy J., Cohen C., et al. Adiponectin modulates C-jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma. Gastroenterology 2010, 139. 1762-73, 1773 e1-5.
131. Seki E., Brenner D.A., Karin M. A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches. Gastroenterology 2012, 143:307-320.
132. Seki E., De Minicis S., Osterreicher C.H., Kluwe J., Osawa Y., Brenner D.A., et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat. Med. 2007, 13:1324-1332.
133. Sepulveda A.R., Finegold M.J., Smith B., Slagle B.L., DeMayo J.L., Shen R.F., et al. Development of a transgenic mouse system for the analysis of stages in liver carcinogenesis using tissue-specific expression of SV40 large T-antigen controlled by regulatory elements of the human alpha-1-antitrypsin gene. Cancer Res. 1989, 49:6108-6117.
134. Shachaf C.M., Kopelman A.M., Arvanitis C., Karlsson A., Beer S., Mandl S., et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 2004, 431:1112-1117.
135. Shimizu M., Tanaka T., Moriwaki H. Obesity and hepatocellular carcinoma: targeting obesity-related inflammation for chemoprevention of liver carcinogenesis. Semin. Immunopathol. 2013, 35:191-202.
136. Shultz L.D., Ishikawa F., Greiner D.L. Humanized mice in translational biomedical research. Nat. Rev. Immunol. 2007, 7:118-130.
137. Siegel A.B., Olsen S.K., Magun A., Brown R.S. Sorafenib: where do we go from here?. Hepatology 2010, 52:360-369.
138. Singh M., Johnson L. Using genetically engineered mouse models of cancer to aid drug development: an industry perspective. Clin. Cancer Res. 2006, 12:5312-5328.
139. Smedley D., Salimova E., Rosenthal N. Cre recombinase resources for conditional mouse mutagenesis. Methods 2011, 53:411-416.
140. Smit J.J., Schinkel A.H., Oude Elferink R.P., Groen A.K., Wagenaar E., van Deemter L., et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 1993, 75:451-462.
141. Stahl S., Ittrich C., Marx-Stoelting P., Kohle C., Altug-Teber O., Riess O., et al. Genotype-phenotype relationships in hepatocellular tumors from mice and man. Hepatology 2005, 42:353-361.
142. Strange K. The end of "naive reductionism": rise of systems biology or renaissance of physiology?. Am. J. Physiol. Cell. Physiol. 2005, 288:C968-C974.
143. Su W.H., Chao C.C., Yeh S.H., Chen D.S., Chen P.J., Jou Y.S. OncoDB.HCC: an integrated oncogenomic database of hepatocellular carcinoma revealed aberrant cancer target genes and loci. Nucleic Acids Res. 2007, 35:D727-D731.
144. Suda T., Liu D. Hydrodynamic gene delivery: its principles and applications. Mol. Ther. 2007, 15:2063-2069.
145. Sun B., Karin M. Obesity, inflammation, and liver cancer. J. Hepatol. 2012, 56:704-713.
146. Tanaka N., Moriya K., Kiyosawa K., Koike K., Gonzalez F.J., Aoyama T. PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. J. Clin. Invest. 2008, 118:683-694.
147. Tang F.Y., Pai M.H., Chiang E.P. Consumption of high-fat diet induces tumor progression and epithelial-mesenchymal transition of colorectal cancer in a mouse xenograft model. J. Nutr. Biochem. 2012, 23:1302-1313.
148. Taniguchi K., Roberts L.R., Aderca I.N., Dong X., Qian C., Murphy L.M., et al. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene 2002, 21:4863-4871.
149. Tentler J.J., Tan A.C., Weekes C.D., Jimeno A., Leong S., Pitts T.M., et al. Patient-derived tumour xenografts as models for oncology drug development. Nat. Rev. Clin. Oncol. 2012, 9:338-350.
150. Thompson M.D., Monga S.P. WNT/beta-catenin signaling in liver health and disease. Hepatology 2007, 45:1298-1305.
151. Thorgeirsson S.S., Grisham J.W. Molecular pathogenesis of human hepatocellular carcinoma. Nat. Genet. 2002, 31:339-346.
152. Tovar V., Alsinet C., Villanueva A., Hoshida Y., Chiang D.Y., Sole M., et al. IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J. Hepatol. 2010, 52:550-559.
153. Turnbaugh P.J., Ridaura V.K., Faith J.J., Rey F.E., Knight R., Gordon J.I. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci. Transl Med. 2009, 1:6ra14.
154. Tward A.D., Jones K.D., Yant S., Cheung S.T., Fan S.T., Chen X., et al. Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:14771-14776.
155. Uysal K.T., Wiesbrock S.M., Marino M.W., Hotamisligil G.S. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997, 389:610-614.
156. Villanueva A., Llovet J.M. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011, 140:1410-1426.
157. von Werder A., Seidler B., Schmid R.M., Schneider G., Saur D. Production of avian retroviruses and tissue-specific somatic retroviral gene transfer in vivo using the RCAS/TVA system. Nat. Protoc. 2012, 7:1167-1183.
158. Wang R., Ferrell L.D., Faouzi S., Maher J.J., Bishop J.M. Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J. Cell. Biol. 2001, 153:1023-1034.
159. Wangensteen K.J., Wilber A., Keng V.W., He Z., Matise I., Wangensteen L., et al. A facile method for somatic, lifelong manipulation of multiple genes in the mouse liver. Hepatology 2008, 47:1714-1724.
160. Ward J.M., Fox J.G., Anver M.R., Haines D.C., George C.V., Collins M.J., et al. Chronic active hepatitis and associated liver tumors in mice caused by a persistent bacterial infection with a novel Helicobacter species. J. Natl. Cancer Inst. 1994, 86:1222-1227.
161. Watson M.R., Wallace K., Gieling R.G., Manas D.M., Jaffray E., Hay R.T., et al. NF-kappaB is a critical regulator of the survival of rodent and human hepatic myofibroblasts. J. Hepatol. 2008, 48:589-597.
162. Wu C.W., Farrell G.C., Yu J. Functional role of PPARgamma in hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2012, 27:1665-1669.
163. Yamashita T., Honda M., Takatori H., Nishino R., Minato H., Takamura H., et al. Activation of lipogenic pathway correlates with cell proliferation and poor prognosis in hepatocellular carcinoma. J. Hepatol. 2009, 50:100-110.
164. Yeh S.H., Chen P.J. Gender disparity of hepatocellular carcinoma: the roles of sex hormones. Oncology 2010, 78(Suppl. 1):172-179.
165. Yu J., Shen B., Chu E.S., Teoh N., Cheung K.F., Wu C.W., et al. Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro. Hepatology 2010, 51:2008-2019.
166. Zender L., Lowe S.W. Integrative oncogenomic approaches for accelerated cancer-gene discovery. Curr. Opin. Oncol. 2008, 20:72-76.
167. Zender L., Spector M.S., Xue W., Flemming P., Cordon-Cardo C., Silke J., et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006, 125:1253-1267.
168. Zender L., Xue W., Zuber J., Semighini C.P., Krasnitz A., Ma B., et al. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 2008, 135:852-864.
169. Zhang G., Budker V., Wolff J.A. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum. Gene Ther. 1999, 10:1735-1737.
170. Zhang Y.W., Su Y., Lanning N., Gustafson M., Shinomiya N., Zhao P., et al. Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor. Oncogene 2005, 24:101-106.
171. Zhang Z. Genomic landscape of liver cancer. Nat. Genet. 2012, 44:1075-1077.